AndroGel maker AbbVie has won its second jury verdict in a row. The manufacturer’s wins follow a jury ruling in March ordering the company to pay $3.2 million to a man injured by its testosterone replacement therapy.
A federal jury in Chicago handed up the most recent verdict June 14, 2018. Jurors found against plaintiff Robert Rowley.
Rowley, of Utah, blamed AndroGel for a blood clot he suffered in April 2013. He also blamed the drug for a second clot he suffered in late 2015.
Last month, another jury ruled against plaintiff Arthur Myers of Arizona. On June 13, 2018, Myers filed a motion for a new trial.
The cases are among more than 6,000 testosterone lawsuits pending in federal court. AbbVie says it faces about 200 more cases in various state courts.
The testosterone lawsuits were filed by men who blame Androgel for heart attacks, strokes and blood clots. The Androgel lawsuits are part of a larger multidistrict litigation (MDL) involving men who say they were harmed by testosterone replacement therapy (TRT) drugs.
Federal courts manage large numbers of lawsuits involving the same issues by way of MDLs. Under this arrangement, a single judge presides over all cases filed nationwide for pretrial matters. The MDL judge also presides over the first trials, known as bellwethers. Bellwether trials are intended to give parties guidance in settlement negotiations.
So far, the AndroGel trials have ended with mixed results. Two cases ended with verdicts in favor of patients. One jury ordered AbbVie to pay $140 million. Another jury ordered the drugmaker to pay $150 million. That larger verdict was overturned. A second trial in April 2018 ended in a verdict of $3.2 million.
Four other trials, including the most recent cases, ended in verdicts in favor of AbbVie. The latest verdict capped the sixth federal bellwether trial involving AndroGel injury claims.
U.S. District Judge Matthew F. Kennelly has scheduled 19 more AndroGel trials from Oct. 2, 2018, through March 4, 2019.
In May 2018, the judge dismissed about 160 cases when the plaintiffs failed to respond to requests for more information about their claims.
Drugwatch.com writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.
Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.
Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.(888) 645-1617